Picture of Blueprint Medicines logo

BPMC — Blueprint Medicines News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapNeutral

Blueprint Medicines Corp reports results for the quarter ended in September 30 - Earnings Summary

* Blueprint Medicines Corp  BPMC.OQ  reported a quarterly
adjusted
loss of 89 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-2.20.  The mean expectation of
nineteen analysts for the quarter was for a loss of 96 cents per
share. Wall Street expected results to range from $-1.12 to -71
cents per share.
    * Revenue rose 126.6% to $128.18 million from a year ago;
analysts
expected $127.03 million. 
    * Blueprint Medicines Corp's reported EPS for the quarter
was a
loss of 89 cents​.
    * The company reported a quarterly loss of $56.28 million.
    * Blueprint Medicines Corp shares had fallen by 9.8% this
quarter and lost 9.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 18.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Blueprint
Medicines Corp is 128.50 
This summary was machine generated from LSEG data October 30 at
03:17 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.96          -0.89          Beat
 Jun. 30 2024      -1.29          -0.80          Beat
 Mar. 31 2024      -1.66          -1.32          Beat
 Dec. 31 2023      -2.04          -1.82          Beat

Recent news on Blueprint Medicines

See all news